悦康药业股价跌5.15%，易方达基金旗下1只基金位居十大流通股东，持有976.65万股浮亏损失1220.81万元

Core Viewpoint - Yuyuan Pharmaceutical's stock has experienced a significant decline, dropping 5.15% on February 2, with a total market value of 10.355 billion yuan and a cumulative drop of 10.64% over the past five days [1] Group 1: Company Overview - Yuyuan Pharmaceutical Group Co., Ltd. is located in Beijing and was established on August 14, 2001, with its listing date on December 24, 2020 [1] - The company focuses on the research and production of high-end chemical drugs, with major revenue contributions from cardiovascular drugs, digestive system drugs, diabetes medications, and anti-infection drugs [1] - Key products contributing to revenue include Ginkgo biloba extract injection, Tianma injection, Lansoprazole injection, Omeprazole enteric-coated capsules, Metformin sustained-release tablets, Cefuroxime sodium injection, and Ceftriaxone sodium injection [1] Group 2: Revenue Composition - The revenue composition of Yuyuan Pharmaceutical is as follows: - Cardiovascular drugs: 55.67% - Anti-infection drugs: 20.88% - Raw materials: 8.73% - Digestive system drugs: 6.87% - Diabetes medications: 4.85% - Others: 2.62% - Supplementary: 0.36% - Technical services: 0.02% [1] Group 3: Shareholder Information - E Fund's healthcare mixed fund (110023) is among the top ten circulating shareholders of Yuyuan Pharmaceutical, having increased its holdings by 2.17% to 9.7665 million shares [2] - The fund has incurred a floating loss of approximately 12.2081 million yuan today and a total floating loss of 28.2252 million yuan over the past five days [2] Group 4: Fund Performance - The fund manager of E Fund's healthcare mixed fund is Yang Zhenshao, who has a tenure of 9 years and 169 days, with a total asset scale of 7.952 billion yuan [3] - The fund has achieved a best return of 201.37% and a worst return of -19.69% during Yang's tenure [3]